News & Filings
PPLPHARMA \u2014 Recent Activity
5 items in the last 14 days
Indian contract drug maker Divi's misses profit view on high material costs, one-off labour charge
Feb 11 (Reuters) - Indian contract drug manufacturer Divi's Laboratories reported third-quarter profit below estimates on Wednesday, as high raw material costs and a one-off charge due to changes in
Click to open →
Piramal Pharma Ltd (BOM:543635) Q3 2026 Earnings Call Highlights: Navigating Challenges and ...
Piramal Pharma Ltd (BOM:543635) shows resilience with strategic acquisitions and growth in consumer healthcare amidst revenue challenges.
Click to open →
Piramal Pharma Ltd (BOM:543635) Q2 2026 Earnings Call Highlights: Navigating Challenges with ...
Piramal Pharma Ltd (BOM:543635) reports steady consumer healthcare growth and strategic expansions despite revenue challenges in Q2 FY26.
Click to open →
Piramal Pharma Ltd (BOM:543635) Q2 2026 Earnings Call Highlights: Navigating Challenges and ...
Piramal Pharma Ltd (BOM:543635) showcases resilience with strategic growth in e-commerce and consumer healthcare amidst revenue challenges.
Click to open →
Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports
Private equity firm Carlyle Group is preparing to offload up to a 10% stake in India's Piramal Pharma, online news portal Moneycontrol reported on Thursday, citing sources. The U.S.-based firm could earn in the range of 26 billion rupees ($304.8 million) to 27 billion rupees from the sale via block trades, the report added. Carlyle Group and Piramal Pharma did not immediately respond to Reuters requests for comment.
Click to open →
Get alerts for important filings
Add PPLPHARMA to your watchlist for board meeting & dividend alerts.
Open analysis →News from yfinance + BSE corporate announcements. Importance scoring is automated. YieldIQ is not registered with SEBI as an investment adviser.